AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03204266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine recovery supplement
Description: Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
Study NCT03204266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
Study NCT02985593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Study NCT02985593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01467687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil controlled release
Description: verapamil 300 mg controlled release capsule as a single dose
Study NCT03322709 — intervention group
Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
Study NCT00534443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy of upper GI tract
Description: Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines.
Study NCT02076022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Fat Grafting
Description: The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject.
Study NCT03355547 — intervention group
Intervention type: OTHER
Intervention: questionnaire about the severity of their symptoms of upper respiratory tract infection
Description: Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
Study NCT03400267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Study NCT03400267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Study NCT04453943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Walking - with or without FES
Description: The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
Study NCT04453943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Sitting to Standing - with or without FES
Description: The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
Study NCT00950885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Melatonin
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
Study NCT00950885 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
Study NCT00950885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Melatonin
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
Study NCT02773784 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry and/or FISH
Description: Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
Study NCT01120782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens with new wetting agent
Description: Investigational toric contact lens made of etafilcon A material with a new wetting agent.
Study NCT01120782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens
Description: Marketed toric contact lens made of etafilcon A material.
Study NCT03255629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: glucagon
Description: novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
Study NCT03255629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closed loop glucagon pump
Description: a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
Study NCT02191215 — intervention group
Intervention type: DRUG
Intervention: Nevirapine (Viramune®)
Study NCT04203277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVY
Description: a combination of practice education and quality improvement interventions
Study NCT02965092 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Second generation CAR-T cells
Study NCT04231552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Study NCT03717428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily Weighing Group
Description: The Experimental group will weigh themselves everyday
Study NCT03717428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
Study NCT03112954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal-relaxant formula
Description: Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
Study NCT03112954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
Study NCT00655915 — intervention group
Intervention type: OTHER
Intervention: Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine
Description: Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
Study NCT01147627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide injection
Description: Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
Study NCT01147627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R
Description: Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
Study NCT01147627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
Study NCT04034797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photography teletransmission
Description: A photography of the trauma is teletransmitted to SAMU's physician
Study NCT04034797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No photo
Description: Usual management without photography teletransmission
Study NCT00973297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary falls prevention
Description: Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
Study NCT00815854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 5 mg of folic acid taken daily for 3 months in an open label fashion
Study NCT00815854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects may receive placebo (a sugar pill) for 4 months
Study NCT01271582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, 5FU, leucovorin
Description: FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
Study NCT02086006 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
Study NCT01160419 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel 50 mg/m2, 1-hour-Infusion, day 1
Description: 50 mg/m2, 1-hour-Infusion, day 1
Study NCT02076022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard fat graft
Description: Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
Study NCT01160419 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1
Description: 85 mg/m², 2-hour-Infusion, day 1
Study NCT01160419 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1
Description: 200 mg/m², 1-2-hour-Infusion, day 1
Study NCT04756752 — intervention group
Intervention type: OTHER
Intervention: Fit and Vitaal program
Description: Intervention type: training
Study NCT01160419 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU 2600 mg/m², 24-hour-Infusion, day 1
Description: 2600 mg/m², 24-hour-Infusion, day 1
Study NCT03897140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: Limited Echocardiogram
Description: STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
Study NCT02379130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
Study NCT02379130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play and Nutrition Intervention
Description: The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
Study NCT02921464 — intervention group
Intervention type: OTHER
Intervention: none - registry clinic followup only
Study NCT02082340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TB knowledge and socio-psychological counseling session
Description: TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
Study NCT03611478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Probiotic capsule
Study NCT03611478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in taste and appearance to probiotic capsule
Study NCT01428830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7-day catheterization following fistula repair surgery
Description: This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
Study NCT01428830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 14 day catheterization
Description: This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
Study NCT02003547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076
Study NCT02190019 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostar repetitive transcranial magnetic stimulator
Description: The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
Study NCT02082340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text messages
Description: TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
Study NCT02082340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone calls
Description: Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
Study NCT02003547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02082340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered drug intake strategy
Description: Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
Study NCT02082340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational leaflet
Description: Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
Study NCT02114658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar,BAY43-9006)
Description: Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
Study NCT02651753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor + Lipidil supra
Description: Reference Drug: Lipitor + Lipidil supra
Study NCT02651753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-337
Description: Test Drug: CKD-337
Study NCT05315908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community outreach method
Description: The method includes automated call and text messaging to increase testing for COVID-19
Study NCT01625260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
Study NCT01625260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
Study NCT02922699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEZ 40
Description: Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
Study NCT02922699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMEZ 80
Description: Omez 80 patients for 58days along with Amoxicilin and Clarithromycin